Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBT Margin (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed EBT Margin for 15 consecutive years, with 4.9% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1267.0% to 4.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.73% through Dec 2025, down 1519.0% year-over-year, with the annual reading at 8.73% for FY2025, 1519.0% down from the prior year.
  • EBT Margin hit 4.9% in Q4 2025 for Corcept Therapeutics, down from 7.34% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 37.77% in Q3 2021 to a low of 4.9% in Q4 2025.
  • Historically, EBT Margin has averaged 24.16% across 5 years, with a median of 26.29% in 2023.
  • Biggest five-year swings in EBT Margin: surged 841bps in 2021 and later crashed -2166bps in 2025.
  • Year by year, EBT Margin stood at 37.17% in 2021, then tumbled by -37bps to 23.56% in 2022, then rose by 15bps to 27.18% in 2023, then tumbled by -35bps to 17.57% in 2024, then tumbled by -72bps to 4.9% in 2025.
  • Business Quant data shows EBT Margin for CORT at 4.9% in Q4 2025, 7.34% in Q3 2025, and 16.3% in Q2 2025.